Hit enter to search or ESC to close
Immuneering Corporation
  • ABOUT
    • Our Approach
    • Team
    • Partnerships
    • In The News
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
  • ABOUT
    • Our Approach
    • Team
    • Partnerships
    • In The News
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
All Posts By

immun-ops2020

immun-ops2020 In Publications

Deep Cyclic Inhibition of MEK: A Transformational Approach to Durable and Safe Combinations in Ras-Mutant Cancers

Presented at the 7th Annual RAS-Targeted Drug Development Summit in Boston on September 17th, 2025. 

Read More
immun-ops2020 In News

September 2025 – The Scientist

A Slow and Steady Approach to Pancreatic Cancer Therapy

Read More
immun-ops2020 In News

July 2025 – Pharmaceutical Executive

Changing the Ways We Treat Cancer

Read More
immun-ops2020 In News

July 2025 – Forbes

A Slow And Steady Approach To Cancer Fighting

Read More
immun-ops2020 In News

July 2025 – PharmaVoice

The MEK effect on cancer — a slow and steady approach to drug resistance

Read More
immun-ops2020 In News

June 2025 – Targeted Oncology

Atebimetinib Combination Shows Promising Survival Data in Pancreatic Cancer

Read More
immun-ops2020 In News

June 2025 – OncLive

Atebimetinib Plus Chemo Displays Potential Survival Benefit in First-Line Pancreatic Cancer

Read More
immun-ops2020 In News

June 2025 – Fierce Biotech

Immuneering sees 94% survival at 6 months in pancreatic cancer, teeing up pivotal trial plans

Read More
immun-ops2020 In News

June 2025 – Cancer Network

Atebimetinib Plus SOC Chemo Improves Survival, Responses in Front-Line PDAC

Read More
immun-ops2020 In News

June 2025 – FirstWord Pharma

Immuneering touts strong survival in pancreatic cancer trial

Read More
1 2 3 … 10 Next
Immuneering logo
  • ABOUT
  • PLATFORM
  • PIPELINE
  • PUBLICATIONS
  • FOR INVESTORS
  • CONTACT
  • Terms of Use
  • Privacy Policy

© 2025 Immuneering Corporation.